Second-generation human adenovirus (hAd5) targeting multiple tumor associated antigens (PSA, MUC-1, Brachyury) demonstrated safety, with no dose-limiting toxicities in patients with advanced prostate ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results